Belman M J, Botnick W C, Shin J W
Division of Pulmonary Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA.
Am J Respir Crit Care Med. 1996 Mar;153(3):967-75. doi: 10.1164/ajrccm.153.3.8630581.
Dynamic hyperinflation (DH) is a major pathophysiologic consequence of airflow limitation during exercise in patients with chronic obstructive pulmonary disease (COPD) and an important contributing factor to breathlessness. In this study we aimed to examine the effect of inhaled beta agonist therapy on DH during exercise in these patients and the relationship between changes in DH and breathlessness. In 13 COPD patients (mean age 65.1 +/- 2.0, FEV1 1.20 +/- 0.17, FEV1/FVC 40 +/- 3) we measured pulmonary function tests, exercise breathlessness by Borg score, and exercise flow volume and pressure volume loops on two separate days. Prior to testing, patients randomly received inhaled placebo or albuterol on the first test day and the alternative medication on the second test day. From measurements of exercise inspiratory capacity (IC), we calculated the end-expiratory and end-inspiratory lung volumes (EELV, EILV). We used esophageal pressure recordings to measure peak inspiratory esophageal pressure (Pesins) during exercise and this was related to the maximal capacity for pressure generation taking into account lung volume and airflow changes (Pcapi). Bronchodilator caused significant increase in both FEV1 and FVC (+0.23 and +0.51, p<0.01). Comparisons of breathlessness, exercise volumes, and pressures were made at the highest equivalent work load. There was a significant reduction in the peak exercise EELV/TLC (80 +/- 0.02% to 76 +/- 0.02%, p<0.05) while the peak EILV/TLC decreased by 2% (97 +/- 1% to 95 +/- 1%, p<0.05). The peak Pesins/Pcapi decreased (0.79 +/- 0.10 to 0.57 +/- 0.05, p<0.05), and the Pcapi - Pesins increased (7.4 +/- 3 to 13.0 +/- 3 cm H2O, p<0.05). There was significant improvement in neuroventilatory coupling for volume change (Pesins/Pcapi/VT/TLC 5.45 +/- 0.5 to 3.25 +/- 1.0, p<0.05). There was a significant reduction in breathlessness as measured by Borg score (4.5 +/- 0.7 to 3.1 +/- 0.5, p<0.05) and there was a significant correlation between delta Borg and delta EILV/TLC (r=0.771, p<0.01) with a trend for Pesins/Pcapi/VT/TLC (r=0.544, p=0.067). There was also a significant correlation between delta EELV/TLC and delta Pesins/Pcapi/VT/TLC (r=0.772, p<0.01). The relationships between delta Borg, delta resting volumes, and flow rates were not significant. We conclude that in patients with COPD, inhaled bronchodilator reduces exercise DH and improves inspiratory pressure reserve and neuroventilatory coupling. Changes in DH and neuroventilatory coupling were the main determinants of reduced breathlessness.
动态肺过度充气(DH)是慢性阻塞性肺疾病(COPD)患者运动期间气流受限的主要病理生理后果,也是导致呼吸困难的一个重要因素。在本研究中,我们旨在探讨吸入β受体激动剂治疗对这些患者运动期间DH的影响以及DH变化与呼吸困难之间的关系。在13例COPD患者(平均年龄65.1±2.0岁,第一秒用力呼气容积[FEV1]为1.20±0.17,FEV1/用力肺活量[FVC]为40±3)中,我们在两个不同日期测量了肺功能测试、采用Borg评分评估的运动性呼吸困难以及运动流量容积和压力容积环。在测试前,患者在第一个测试日随机接受吸入安慰剂或沙丁胺醇,在第二个测试日接受另一种药物。根据运动吸气容量(IC)的测量结果,我们计算了呼气末和吸气末肺容积(EELV、EILV)。我们使用食管压力记录来测量运动期间的吸气峰值食管压力(Pesins),并根据肺容积和气流变化将其与最大压力产生能力(Pcapi)相关联。支气管扩张剂使FEV1和FVC均显著增加(分别增加0.23和0.51,p<0.01)。在最高等效工作负荷下对呼吸困难、运动容积和压力进行了比较。运动峰值EELV/肺总量(TLC)显著降低(从80±0.02%降至76±0.02%,p<0.05),而峰值EILV/TLC降低了2%(从97±1%降至95±1%,p<0.05)。峰值Pesins/Pcapi降低(从0.79±0.10降至0.57±0.05,p<0.05),且Pcapi - Pesins增加(从7.4±3增至13.0±3 cmH₂O,p<0.05)。容积变化的神经通气耦合有显著改善(Pesins/Pcapi/潮气量[VT]/TLC从5.45±
0.5降至3.25±1.0,p<0.05)。采用Borg评分评估的呼吸困难有显著降低(从4.5±0.7降至3.1±0.5,p<0.05),Borg评分变化量(delta Borg)与EILV/TLC变化量之间存在显著相关性(r = 0.771,p<0.01),Pesins/Pcapi/VT/TLC有相关趋势(r = 0.544,p = 0.067)。EELV/TLC变化量与Pesins/Pcapi/VT/TLC变化量之间也存在显著相关性(r = 0.772,p<0.01)。delta Borg、静息容积变化量和流速之间的关系不显著。我们得出结论,在COPD患者中,吸入支气管扩张剂可减少运动性DH并改善吸气压力储备和神经通气耦合。DH和神经通气耦合的变化是呼吸困难减轻的主要决定因素。